1. In Vivo
  2. >>Leadership

AI Driving Innovation: Insights From Exscientia CEO Andrew Hopkins

 
• By Lucie Ellis-Taitt and David Wild

Andrew Hopkins, founder and CEO of Exscientia, invented and championed an algorithmic approach to drug design and drug discovery. He talks to In Vivo about artificial intelligence in the biopharma industry today and what lies ahead. 

AI drug development concept
• Source: Shutterstock

Founded back in 2012, Exscientia plc went public on Nasdaq in October 2021, raising over $300m – a huge amount for a biotech that is yet to bring a drug into the clinic on its own. However, it was ahead of the game being the first company to automate drug design and the first to have an AI-designed molecule enter clinical trials (albeit a partnered asset).

The company’s most advanced, wholly owned drugs are in IND-enabling studies. EXS74539 is a selective, reversible and brain penetrant LSD1...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 
• By Edwin Elmhirst

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 
• By Anabel Costa-Ferreira

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.